Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ID: DRG0SSFSR)
| ADC Name |
DM001
|
|||||
|---|---|---|---|---|---|---|
| Synonyms |
DM001; DM001 (Doma); BCG011
Click to Show/Hide
|
|||||
| Organization |
Biocytogen (Originator);Sidao Medicine
|
|||||
| Drug Status |
Phase 1
|
|||||
| Drug-to-Antibody Ratio |
8
|
|||||
| Structure |
|
|||||
|
|
||||||
| Antibody Name |
Anti-EGFR/TROP2 bsAb
|
Antibody Info | ||||
| Antigen Name |
Epidermal growth factor receptor (EGFR); Tumor-associated calcium signal transducer 2 (TACSTD2)
|
Antigen Info | ||||
| Payload Name |
BCPT02
|
Payload Info | ||||
| Payload Target |
DNA topoisomerase 1 (TOP1)
|
Target Info | ||||
| Linker Name |
Hydrophilic, protease-cleavable linker
|
Linker Info | ||||
| Conjugate Type |
Undisclosed
|
|||||
| Combination Type |
BLD1102
|
|||||
2027 Update
The disease landscape of This ADC
2027 Update
The clinical trial pipelines of This ADC
| Disease Name | Phase 1 | Phase 2 | Phase 3 | Approved |
|---|---|---|---|---|
| Gastroesophageal junction adenocarcinoma | ||||
| Gastric cancer | ||||
| Colorectal cancer | ||||
| Lung cancer | ||||
| Breast cancer |
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Patients Enrolled |
Key inclusion criteria: signed consent; age ≥18; ECOG 0-1; metastatic breast cancer/EGFRmut or EGFRwt NSCLC/gastric/CRC refractory to standard therapy; measurable disease (RECIST 1.1); life expectancy ≥3 months.
|
||||
| Administration Dosage |
Subjects may continue to receive DM001 (with an increased dose that has been assessed as safe in the dose-escalation period) once every 3 weeks (Q3W) for a total of 6 cycles at the discretion of the investigators, until unacceptable toxicity, progressive disease (PD), or withdrawal of consent.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT06475937 | Clinical Status | PHASE1 | ||
| Clinical Description | A Phase I, Multicenter, Open-label, First-in-Human, Dose Escalation and Expansion Study of DM001 in Patients with Advanced Solid Tumors | ||||
| Primary Endpoint |
Primary endpoints include DLT incidence (grade 3 neurological/grade 4 toxicities) and MTD determination (dose with ≤1/6 DLTs) for DM001 over 12 months.
|
||||
| Other Endpoint |
Secondary endpoints comprise PK parameters (AUC0-inf, Cmax, Tmax, Ctrough) and ORR (CR+PR per RECIST 1.1), all evaluated over 12 months.
|
||||